Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.

Article  Google Scholar 

Taylor I. Liver metastases from colorectal cancer: Lessons from past and present clinical studies. Br J Surg. 1996;83(4):456–60. https://doi.org/10.1002/bjs.1800830406.

CAS  Article  PubMed  Google Scholar 

Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surgery, Gynecology & Obstetrics 1992;174 (1), 27–32. https://pubmed.ncbi.nlm.nih.gov/1729745/

Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier A-M. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59(10):1383–8. https://doi.org/10.1136/gut.2010.211557.

Article  PubMed  Google Scholar 

Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Scientific Reports. 2016; 6(1). https://doi.org/10.1038/srep29765

Gloeckler Ries LA. Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6):541–52. https://doi.org/10.1634/theoncologist.8-6-541.

Article  PubMed  Google Scholar 

Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28-37. https://doi.org/10.1016/S1470-2045(12)70510-7.

Article  PubMed  Google Scholar 

Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82. https://doi.org/10.1016/S1470-2045(16)30532-0.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. https://doi.org/10.1001/jamaoncol.2017.3501.

Article  PubMed  Google Scholar 

Sauter ER, Bolton JS, Willis GW, Farr GH, Sardi A. Improved survival after pulmonary resection of metastatic colorectal carcinoma. J Surg Oncol. 1990;43(3):135–8. https://doi.org/10.1002/jso.2930430303.

CAS  Article  PubMed  Google Scholar 

Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M, Chua YJ, Craft P, Piantadosi C, Sorich M, Gibbs P, Yip D. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncologica (Stockholm, Sweden). 2018;57(11):1438–44. https://doi.org/10.1080/0284186X.2018.1487581.

CAS  Article  Google Scholar 

Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, Lu D. Local surgical, ablative, and radiation treatment of metastases. CA A Cancer J Clin. 2009;59(3):145–70.

Article  Google Scholar 

Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, Alongi F, Clerici E, Lobefalo F, Tozzi A, Reggiori G, Fogliata A, Scorsetti M. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiation Oncology. 2004;9(1). https://doi.org/10.1186/1748-717x-9-91

Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, Botticella A, Ciammella P, Iftode C, Buffoni L, Ruffini E, Scagliotti GV. Stereotactic body radiation therapy for lung metastases. Lung Cancer (Amsterdam, Netherlands). 2012;75(1):77–81. https://doi.org/10.1016/j.lungcan.2011.04.021.

Article  Google Scholar 

Wang Z, Wang X, Yuan J, Zhang X, Zhou J, Lu M, Liu D, Li J, Shen L. Survival benefit of palliative local treatments and efficacy of different pharmacotherapies in colorectal cancer with lung metastasis: results from a large retrospective study. Clin Colorectal Cancer. 2018;17(2):e233–55. https://doi.org/10.1016/j.clcc.2017.12.005.

Article  PubMed  Google Scholar 

Tampellini M, Ottone A, Bellini E, Alabiso I, Baratelli C, Bitossi R, Brizzi MP, Ferrero A, Sperti E, Leone F, Miraglia S, Forti L, Bertona E, Ardissone F, Berruti A, Alabiso O, Aglietta M, Scagliotti GV. The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. Oncologist. 2012;17(11):1430–8. https://doi.org/10.1634/theoncologist.2012-0142.

Article  PubMed  PubMed Central  Google Scholar 

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard J-Y, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. https://doi.org/10.1093/annonc/mdw235.

Article  PubMed  Google Scholar 

• Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward WA. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology. 2020;148:157–66. https://doi.org/10.1016/j.radonc.2020.04.003. (ESTRO and ASTRO consensus definitions for oligometastatic disease. Defined OMD as 1-5 metastatic lesions, a controlled primary tumor being optional, but where all metastatic sites must be safely treatable.)

Article  Google Scholar 

• Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans A-MC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://doi.org/10.1016/S1470-2045(19)30718-1. (. ESTRO/EORTC proposal for new classification system for oligometastatic disease. Proposed classification system including 9 different oligometastatic “states” based on history of polymetastatic disease, repeat vs. de-novo oligometastatic disease, synchronous vs. metachronous oligometastatic disease, and oligorecurrence vs. oligoprogression vs. oligopersistent disease.)

Article  PubMed  Google Scholar 

Pfannschmidt J, Hoffmann H, Dienemann H. Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thor Oncol. 2010;5(6 Suppl 2):S172-178. https://doi.org/10.1097/JTO.0b013e3181dca330.

Article  Google Scholar 

Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RLE, Navarria P, Ascolese A, Tozzi A, Iftode C, De Rose F, Villa E, Personeni N, Rimassa L, Santoro A, Fogliata A, Mancosu P, Tomatis S, Scorsetti M. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14:619. https://doi.org/10.1186/1471-2407-14-619.

Article  PubMed  PubMed Central  Google Scholar 

Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84(1):324–38. https://doi.org/10.1016/j.athoracsur.2007.02.093.

Article  PubMed  Google Scholar 

Riquet M, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, Médioni J, Rougier P. Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg. 2010;89(2):375–80. https://doi.org/10.1016/j.athoracsur.2009.10.005.

Article  PubMed  Google Scholar 

Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N. Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. Br J Surg. 2009;96(9):1058–65. https://doi.org/10.1002/bjs.6682.

CAS  Article  PubMed  Google Scholar 

Gonzalez M, Ris HB, Krueger T, Gervaz P. Colorectal cancer and thoracic surgeons: close encounters of the third kind. Expert Rev Anticancer Ther. 2012;12(4):495–503. https://doi.org/10.1586/era.12.21.

CAS  Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. (2019). Colon cancer (version 2.2019). Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

Erhunmwunsee L, Tong BC. Preoperative evaluation and indications for pulmonary metastasectomy. Thorac Cardiovasc Surg. 2016;26(1):7–12. https://doi.org/10.1016/j.thorsurg.2015.09.002.

Article  Google Scholar 

Londero F, Grossi W, Morelli A, Parise O, Masullo G, Tetta C, Livi U, Maessen JG, Gelsomino S. Surgery versus stereotactic radiotherapy for treatment of pulmonary metastases A systematic review of literature. Future Science OA. 2020;6(5):FSO471. https://doi.org/10.2144/fsoa-2019-0120.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Rodríguez-Fuster A, Belda-Sanchis J, Aguiló R, Embun R, Mojal S, Call S, Molins L, Rivas de Andrés JJ. Morbidity and mortality in a large series of surgical patients with pulmonary metastases of colorectal carcinoma: a prospective multicentre Spanish study (GECMP-CCR-SEPAR). Eur J Cardio-Thor Surg. 2014;45(4):671–6. https://doi.org/10.1093/ejcts/ezt459.

Article  Google Scholar 

Fukada M, Matsuhashi N, Takahashi T, Tanaka Y, Okumura N, Yamamoto H, Shirahashi K, Iwata H, Doi K, Yoshida K. Prognostic factors in pulmonary metastasectomy and efficacy of repeat pulmonary metastasectomy from colorectal cancer. World J Surg Oncol. 2020;18(1):314. https://doi.org/10.1186/s12957-020-02076-3.

Article  PubMed  PubMed Central  Google Scholar 

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes H-G. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. https://doi.org/10.1016/s1470-2045(14)70330-4.

CAS  Article  PubMed  Google Scholar 

Cunningham D, Atkin W, Lenz H-J, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet (London, England). 2010;375(9719):1030–47. https://doi.org/10.1016/S0140-6736(10)60353-4.

Article  Google Scholar 

Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20(2):572–9. https://doi.org/10.1245/s10434-012-2726-3.

Article  PubMed  Google Scholar 

Fiorentino F, Hunt I, Teoh K, Treasure T, Utley M. Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis. J R Soc Med. 2010;103(2):60–6. https://doi.org/10.1258/jrsm.2009.090299.

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20(2):572–9. https://doi.org/10.1245/s10434-012-2726-3.

Article  PubMed  Google Scholar 

• Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, Lees B, Grigg O, Fallowfield L, PulMiCC Trial Group. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019;20(1):718. https://doi.org/10.1186/s13063-019-3837-y. (Multi-center randomized controlled trial published in 2019, randomized 65 patients to either surgical metastasectomy or active clinical monitoring. The study had difficulty enrolling patients and was underpowered. There was no significant 5-year survival difference (38% vs 29%, HR 0.82, 95% CI: 0.43-1.56))

CAS  Article  PubMed  PubMed Central  Google Scholar 

• Milosevic M, Edwards J, Tsang D, Dunning J, Shackcloth M, Batchelor T, Coonar A, Hasan J, Davidson B, Marchbank A, Grumett S, Williams NR, Macbeth F, Farewell V, Treasure T. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients – control survival is much better than previously assumed. Colorectal Dis. 2020;22(10):1314–24. https://doi.org/10.1111/codi.15113. (Updated analysis of PulMiCC trial that included 93 patients, reported similar results with no significant difference in survival with median OS 3.8 years for control arm vs 3.5 years for PME arm.)

CAS  Article  PubMed  PubMed Central